Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-EVs in Acute/Acute-on-Chronic Liver Failure
NCT05940610Phase 2Withdrawn
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cell exosomes in acute-on-chronic liver failure (ACLF), acute liver failure (ALF), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Planned start Sep 2023; status: withdrawn.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
acute-on-chronic liver failure (ACLF)acute liver failure (ALF)
Beyond the preview
Go deeper on NCT05940610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940610.